Dolor sit amet lorem ipsum

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.

Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui.

Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna.

Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu.



Christian Angermayer

Founder

Strategy and investor relations

Lars Wilde

Co-Founder

Advising on drug discovery and compound sourcing

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

Simon Seibold

Associate

Investments and business development

Philipp Schreiber

Associate

Drug discovery and compound sourcing

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

Danny Talati

Lead, Business Development

Compound sourcing and evaluating